Glutamic acid decarboxylase 65-specific autoreactive T cell (GAD65-specific T cell)

Glutamic acid decarboxylase 65 (GAD65)-specific autoreactive T cells are a specialized subset of T lymphocytes that play a central role in the autoimmune destruction of pancreatic beta cells in Type 1 Diabetes (T1D) (Source: PubMed, PMID: 22431561). These cells recognize GAD65, an enzyme responsible for GABA synthesis, as a primary autoantigen when presented by specific HLA class II molecules like HLA-DRB1*04:01 (Source: NIH). In addition to T1D, these autoreactive T cells are implicated in the pathogenesis of Stiff-Person Syndrome, where they contribute to the loss of GABAergic neurons in the central nervous system (Source: StatPearls). Therapeutic strategies targeting these cells include antigen-specific immunotherapies, such as the recombinant human GAD65 vaccine (Diamyd), which aims to induce immune tolerance and preserve residual insulin production (Source: Diamyd Medical). Other approaches involve broader T-cell modulators like Teplizumab, which can delay T1D progression by affecting the activation and exhaustion of these autoreactive populations (Source: FDA). Monitoring these cells via ELISPOT assays or tetramer staining serves as a vital biomarker for assessing disease activity and treatment response in clinical trials (Source: PubMed, PMID: 30206000). The ultimate goal of targeting these cells is to achieve precision immune modulation, halting the progression of autoimmunity without compromising the patient's overall immune defense against pathogens.

Other names

GAD65-reactive T cellGAD-specific T lymphocyteGlutamate decarboxylase 2-specific T cellGAD65-autoreactive T-lymphocyte

Induction of antigen-specific immune tolerance to suppress autoreactive T-cell responses or systemic modulation of T-cell activation and proliferation.